Pfizer Ltd. reported unaudited earnings results for the third quarter and nine months ended December 31, 2011. For the quarter, the company reported net sales/income from operations of INR 2,518.8 million against INR 2,358.4 million a year ago. Profit from ordinary activities before tax was INR 721.0 million against INR 659.3 million a year ago. Net profit was INR 482.8 million or INR 16.27 per basic and diluted share before exceptional items and INR 16.18 per basic and diluted share after extraordinary items against net profit of INR 435.8 million or INR 14.67 per basic and diluted share before exceptional items and INR 14.60 per basic and diluted share before and after extraordinary items a year ago. For the nine months, the company reported net sales/income from operations of INR 7,655.7 million against INR 6,737.8 million a year ago. Profit from ordinary activities before tax was INR 2,049.4 million against INR 1,844.3 million a year ago. Net profit was INR 1,365.1 million or INR 45.83 per basic and diluted share before exceptional items and INR 45.75 per basic and diluted share after extraordinary items against net profit of INR 1,207.5 million or INR 41.13 per basic and diluted share before exceptional items and INR 40.46 per basic and diluted share before and after extraordinary items a year ago.